1 Min Read
Jan 3 (Reuters) - Eiger Biopharmaceuticals Inc :
* Eiger announces first patient dosed in open-label extension of phase 2 liberty study of Ubenimex in pulmonary arterial hypertension (pah) Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.